Trials / Completed
CompletedNCT02079168
A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults
A Multi-Center, Prospective, Randomized, Single-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- RXi Pharmaceuticals, Corp. · Industry
- Sex
- All
- Age
- 21 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the effectiveness of RXI-109 in reducing the recurrence of keloid formation following elective keloid excision.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RXI-109 | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2016-03-01
- Completion
- 2016-03-01
- First posted
- 2014-03-05
- Last updated
- 2016-06-14
Locations
3 sites across 2 countries: United States, Dominican Republic
Source: ClinicalTrials.gov record NCT02079168. Inclusion in this directory is not an endorsement.